Bugworks Research Raises $7.5 Million Through A Fresh Round
In a fresh round of funding, Bugworks, a biopharma startup raised Rs 57.30 crore from Tokyo Edge Capital, Global Brain Corporation and Acquipharma Holding. The startup has offices in Delaware and Bangalore. The announcement was made by the startup in ints official release.
“This new financing is an endorsement of our team and differentiated anti-microbial resistance (AMR) assets, as we bring reputed global investors to aid our mission of pandemic preparedness by defeating superbug infections," said Anand Anandkumar, Chief Executive of Bugworks.
